论文部分内容阅读
唑来膦酸(ZOL)是第三代双膦酸盐类药物的典型代表,在已上市的双膦酸盐类药物中应用最广泛、综合疗效最好,现已作为乳腺癌骨转移的常规治疗药物。多项临床前研究及临床研究已证实,唑来膦酸对肿瘤细胞有直接或间接的抑制作用,联合其他辅助治疗(化疗和内分泌治疗)可发挥协同作用,对改善乳腺癌患者术后生存、抑制复发及转移具有重要作用,本文就上述研究进展作一综述。
Zoledronic acid (ZOL) is a typical representative of the third generation of bisphosphonates. It is the most widely used bisphosphonate in the market and has the best combined effect. It has been used as a routine medicine. A number of preclinical studies and clinical studies have confirmed that zoledronic acid on tumor cells have a direct or indirect inhibitory effect, combined with other adjuvant therapy (chemotherapy and endocrine therapy) can play a synergistic effect on improving the survival of patients with breast cancer, Inhibit the recurrence and metastasis has an important role, this article reviews the progress of these studies.